These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27171159)

  • 1. Pancreatic cancer screening using a multiplatform human serum metabolomics system.
    Sakai A; Suzuki M; Kobayashi T; Nishiumi S; Yamanaka K; Hirata Y; Nakagawa T; Azuma T; Yoshida M
    Biomark Med; 2016 Jun; 10(6):577-86. PubMed ID: 27171159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.
    Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics.
    Hirata Y; Kobayashi T; Nishiumi S; Yamanaka K; Nakagawa T; Fujigaki S; Iemoto T; Kobayashi M; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Yamada T; Honda K; Azuma T; Yoshida M
    Clin Chim Acta; 2017 May; 468():98-104. PubMed ID: 28215548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum metabolomics differentiating pancreatic cancer from new-onset diabetes.
    He X; Zhong J; Wang S; Zhou Y; Wang L; Zhang Y; Yuan Y
    Oncotarget; 2017 Apr; 8(17):29116-29124. PubMed ID: 28418859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
    Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
    Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
    Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
    Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel gas chromatography mass spectrometry-based serum diagnostic and assessment approach to ulcerative colitis.
    Kohashi M; Nishiumi S; Ooi M; Yoshie T; Matsubara A; Suzuki M; Hoshi N; Kamikozuru K; Yokoyama Y; Fukunaga K; Nakamura S; Azuma T; Yoshida M
    J Crohns Colitis; 2014 Sep; 8(9):1010-21. PubMed ID: 24582087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry.
    Nishiumi S; Kobayashi T; Kawana S; Unno Y; Sakai T; Okamoto K; Yamada Y; Sudo K; Yamaji T; Saito Y; Kanemitsu Y; Okita NT; Saito H; Tsugane S; Azuma T; Ojima N; Yoshida M
    Oncotarget; 2017 Mar; 8(10):17115-17126. PubMed ID: 28179577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study.
    Ríos Peces S; Díaz Navarro C; Márquez López C; Caba O; Jiménez-Luna C; Melguizo C; Prados JC; Genilloud O; Vicente Pérez F; Pérez Del Palacio J
    SLAS Discov; 2017 Apr; 22(4):348-359. PubMed ID: 27655283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel serum metabolomics-based diagnostic approach for colorectal cancer.
    Nishiumi S; Kobayashi T; Ikeda A; Yoshie T; Kibi M; Izumi Y; Okuno T; Hayashi N; Kawano S; Takenawa T; Azuma T; Yoshida M
    PLoS One; 2012; 7(7):e40459. PubMed ID: 22792336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
    Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
    Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gastroenterological Cancer Diagnosis by Metabolomics-Discovery of Pancreatic Cancer Biomarker].
    Yoshida M; Nishiumi S; Azuma T
    Rinsho Byori; 2015 Apr; 63(4):450-6. PubMed ID: 26536778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis.
    Luo X; Liu J; Wang H; Lu H
    Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity of metabolic colorectal cancer biomarkers in serum through effect size.
    Di Giovanni N; Meuwis MA; Louis E; Focant JF
    Metabolomics; 2020 Aug; 16(8):88. PubMed ID: 32789702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum metabolomics of laryngeal cancer based on liquid chromatography coupled with quadrupole time-of-flight mass spectrometry.
    Zhang X; Hou H; Chen H; Liu Y; Wang A; Hu Q
    Biomed Chromatogr; 2018 May; 32(5):e4181. PubMed ID: 29272549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplatform metabolomics provides insight into the molecular basis of chronic kidney disease.
    Kordalewska M; Macioszek S; Wawrzyniak R; Sikorska-Wiśniewska M; Śledziński T; Chmielewski M; Mika A; Markuszewski MJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jun; 1117():49-57. PubMed ID: 30999273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel serum biomarker for the detection of acute myeloid leukemia based on liquid chromatography-mass spectrometry.
    Wang D; Tan G; Wang H; Chen P; Hao J; Wang Y
    J Pharm Biomed Anal; 2019 Mar; 166():357-363. PubMed ID: 30690249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
    Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
    Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panel of serum metabolites discriminates cancer patients and healthy participants of lung cancer screening - a pilot study.
    Roś-Mazurczyk M; Wojakowska A; Marczak Ł; Polański K; Pietrowska M; Polanska J; Dziadziuszko R; Jassem J; Rzyman W; Widlak P
    Acta Biochim Pol; 2017; 64(3):513-518. PubMed ID: 28803255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
    Xiong Y; Shi C; Zhong F; Liu X; Yang P
    Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.